Clinical Trial Results:
A randomized, double-blind, double dummy, multicenter study to assess the safety, tolerability and long-term efficacy of intravenous (10 mg/kg) and subcutaneous (300 mg) secukinumab in subjects with moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab
Summary
|
|
EudraCT number |
2011-002510-36 |
Trial protocol |
SK CZ GB DE AT PL BG |
Global completion date |
24 Apr 2013
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
13 Apr 2016
|
First version publication date |
13 Apr 2016
|
Other versions |
|
Summary report(s) |
CAIN457A2307 CT.gov results public |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.